{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=10", "query": { "condition": "Locally Advanced and Metastatic Solid Tumors", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+and+Metastatic+Solid+Tumors&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T23:23:47.913Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06069570", "title": "Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung Cancer", "Bone Metastases From Solid Tumors" ], "interventions": [ { "name": "KB-GDT-01", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kiromic BioPharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2023-11-07", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 5, "location_summary": "Tucson, Arizona • Beverly Hills, California • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Tyler", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06069570" }, { "nct_id": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2019-02-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 21, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821935" }, { "nct_id": "NCT07094204", "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non-Small-Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ASP5834", "type": "DRUG" }, { "name": "panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2025-07-25", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 11, "location_summary": "Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094204" }, { "nct_id": "NCT03646071", "title": "A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "RX108", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuPharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-08-01", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646071" }, { "nct_id": "NCT04128423", "title": "Study of AMV564 in Subjects With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "AMV564", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amphivena Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2019-10-09", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 11, "location_summary": "Los Angeles, California • Orlando, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04128423" }, { "nct_id": "NCT00550927", "title": "Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "enzastaurin hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-11", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550927" }, { "nct_id": "NCT04419532", "title": "A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Solid Tumor" ], "interventions": [ { "name": "DS-1055a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-10-09", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 2, "location_summary": "New York, New York • Cincinnati, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419532" }, { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Invasive Breast Lobular Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 138, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT02775292", "title": "Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Childhood Solid Neoplasm", "Metastatic Neoplasm" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL", "type": "BIOLOGICAL" }, { "name": "NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 1, "start_date": "2017-01-03", "completion_date": "2019-04-08", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02775292" }, { "nct_id": "NCT03717415", "title": "A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor" ], "interventions": [ { "name": "Rebastinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2019-01-02", "completion_date": "2022-11-01", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-21T23:23:47.913Z", "location_count": 9, "location_summary": "San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03717415" } ] }